A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

Study ID
NCT02435433

Study type
Interventional

Study phase
Phase 3

Study status
Completed

Trial Acronym

REACH-2

Trial Summary

The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be randomized to ramucirumab or placebo in a 2:1 ratio (Main Global Cohort and China Maximized Extended Enrollment [MEE] Cohort). Participants may also receive ramucirumab if eligible to be enrolled in Open-Label Expansion (OLE) Cohort.

More informations

Trial Starting Date

Jul 20,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

399